Aranesp [使血紅昇] - Taiwan - 全球药品采购网

TOP

Aranesp [使血紅昇]

2014-05-10 17:06:38 来源: 作者: 【大中小】浏览:696次评论:0条

全民健康保險藥品給付規定 / 健保碼及健保價

See related Aranesp inj[使血紅昇注射劑] information

製造商

Amgen

代理/經銷商

Kyowa Hakko Kirin (Taiwan)

成份

Darbepoetin α

適應症

Treatment of anemia associated with chronic renal failure (CRF), including patients either on or not on dialysis. Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.

用量

CRF patients Administered either IV/SC as a single weekly injection. Dose should be started & slowly adjusted to achieve & maintain a target Hb not >12 g/dL. Reduce dose by 25% if rise in Hb is > 1 g/dL in 2 weeks. Correction of anemia Adult Initially 0.45 mcg/kg as single SC/IV once weekly. Conversion From epoetin α to Aranesp Starting weekly dose should be estimated on the basis of the weekly epoetin α dose at the time of substitution. Aranesp should be administered once a week if a patient was receiving epoetin α 2-3 times weekly. Aranesp should be administered once every 2 weeks if a patient was receiving epoetin alfa once per week. Cancer patients receiving chemotherapy 2.25 mcg/kg once weekly or 500 mcg once every 3 weeks as single SC inj. Refer full prescribing information for dosage adjustment.

過量

View Aranesp[使血紅昇] overdosage for action to be taken in the event of an overdose.

美國食品藥物管理局之懷孕等級

Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

禁忌

Uncontrolled HTN.

警告

For additional cautionary notes to warn of the potential risk of using the medicine... click to view Aranesp[使血紅昇] detailed prescribing infomation

注意事項

Closely monitor & control BP during therapy. Folic acid or vit B₁₂ deficiencies, intercurrent infections, inflammatory or malignant processes, osteofibrosis cystica, occult blood loss, hemolysis, severe aluminum toxicity & bone marrow fibrosis may compromise the erythropoietic response. Pregnancy & lactation.

不良反應

Vascular access thrombosis, CHF, sepsis, cardiac arrhythmia, infections, HTN, hypotension, myalgia, headache, diarrhea, fever, nausea, chest pain.
View ADR Monitoring Website[參閱藥物不良反應監測表格]

使用上注意

For caution against possible variation of physical aspect of medicine... click to view Aranesp[使血紅昇] detailed prescribing infomation

儲存

View Aranesp[使血紅昇] storage conditions for details to ensure optimal shelf-life.

描述

View Aranesp[使血紅昇] description for details of the chemical structure and excipients (inactive components).

作用

View Aranesp[使血紅昇] mechanism of action for pharmacodynamics and pharmacokinetics details.

本商品之市售規格

劑型

包裝

圖片